Equity Profile

PAHC

Phibro Animal Health Corporation

Health CarePharmaceuticals$1.3B

Aug26Wed

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

Phibro Animal Health Corporation (PAHC) operates in the health care sector, focusing on pharmaceuticals for animal health. The company plays a crucial role in the agricultural industry by providing products that enhance animal health and productivity, which is increasingly important as global food demand rises.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be keen to see if Phibro continues its trend of beating estimates.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in this area would signal strong demand for Phibro's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PAHC Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

In Q3-2026, Phibro reported an EPS of $0.76, exceeding expectations by 5.85%. Despite this positive surprise, the stock saw a modest increase of 4.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Phibro has consistently beaten EPS estimates, but the lack of revenue guidance leaves uncertainty. Investors will be watching closely to see if this trend continues.

Bull Case

If Phibro can maintain its track record of beating EPS estimates, it could lead to a strong positive reaction in the stock price, especially given the implied volatility in the options market.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied move.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Phibro's EPS exceed $0.76 again this quarter?

Given the company's history of beating EPS estimates, this will be a critical measure of ongoing profitability.

What insights can management provide on revenue trends?

Understanding revenue growth is essential for assessing the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Phibro's ability to maintain its EPS growth, given the company's strong historical performance and market position.

Supporting Evidence

Phibro has consistently beaten EPS estimates in the past, suggesting a strong operational performance.

The options market is pricing in a significant move, indicating that traders expect volatility, which may reflect underlying confidence in the company's results.

Key Risk

If EPS comes in below $0.76, it could challenge the market's current optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Phibro can sustain its profitability amid market challenges.

Bull Confirmed If

An EPS above $0.76 would confirm the bull case and suggest continued strong performance.

Bear Confirmed If

An EPS below $0.76 or weak revenue commentary would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±22.04%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±22.0% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

100.6%

Calls (100)P/C Ratio: 0.14Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats expectations, history suggests a potential stock increase of around +0.37%, confirming the company's strong performance.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

If Phibro misses expectations, the average historical reaction has been a decline of around -2.28%, indicating a negative market response.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on revenue trends and demand for animal health products.
2Insights into cost management and pricing strategies.
3Updates on new product launches or pipeline developments.
4Management's outlook on market conditions and competition.
5Any changes in guidance or expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Sandisk Corporation

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be keen to see if Phibro continues its trend of beating estimates.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in this area would signal strong demand for Phibro's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PAHC Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

In Q3-2026, Phibro reported an EPS of $0.76, exceeding expectations by 5.85%. Despite this positive surprise, the stock saw a modest increase of 4.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Phibro can maintain its track record of beating EPS estimates, it could lead to a strong positive reaction in the stock price, especially given the implied volatility in the options market.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied move.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Phibro's EPS exceed $0.76 again this quarter?

Given the company's history of beating EPS estimates, this will be a critical measure of ongoing profitability.

What insights can management provide on revenue trends?

Understanding revenue growth is essential for assessing the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Phibro's ability to maintain its EPS growth, given the company's strong historical performance and market position.

Supporting Evidence

Phibro has consistently beaten EPS estimates in the past, suggesting a strong operational performance.

The options market is pricing in a significant move, indicating that traders expect volatility, which may reflect underlying confidence in the company's results.

Key Risk

If EPS comes in below $0.76, it could challenge the market's current optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Phibro can sustain its profitability amid market challenges.

Bull Confirmed If

An EPS above $0.76 would confirm the bull case and suggest continued strong performance.

Bear Confirmed If

An EPS below $0.76 or weak revenue commentary would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±22.04%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±22.0% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

100.6%

Calls (100)P/C Ratio: 0.14Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats expectations, history suggests a potential stock increase of around +0.37%, confirming the company's strong performance.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

If Phibro misses expectations, the average historical reaction has been a decline of around -2.28%, indicating a negative market response.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on revenue trends and demand for animal health products.
2Insights into cost management and pricing strategies.
3Updates on new product launches or pipeline developments.
4Management's outlook on market conditions and competition.
5Any changes in guidance or expectations for the next quarter.